Precigen, Inc.

NasdaqGS:PGEN Stock Report

Market Cap: US$2.1b

Precigen Future Growth

Future criteria checks 5/6

Precigen is forecast to grow earnings and revenue by 65.8% and 42.4% per annum respectively while EPS is expected to grow by 67.4% per annum.

Key information

65.8%

Earnings growth rate

67.39%

EPS growth rate

Biotechs earnings growth25.3%
Revenue growth rate42.4%
Future return on equityn/a
Analyst coverage

Low

Last updated12 Jun 2026

Recent future growth updates

Recent updates

Seeking Alpha • Jun 26

Precigen: Entering The Oncology 'Sweet Spot'

Summary Precigen earns a STRONG BUY rating following the commercial success of PAPZIMEOS and rapid revenue growth. PGEN's AdenoVerse platform underpins a validated, scalable franchise, with PAPZIMEOS now endorsed as first-line therapy for RRP and covered by major US insurers. Management projects cash flow breakeven in 2026, with Wall Street revising EPS and revenue estimates sharply since the 1Q earnings call. Risks include competitive threats from INO-3107, but PGEN's commercial momentum remains strong. Read the full article on Seeking Alpha
Narrative Update • Jun 26

PGEN: Orphan Exclusivity And Durable RRP Data Will Drive Future Upside

Analysts have raised their fair value estimate for Precigen from $8.50 to $12.45, citing higher price targets tied to Papzimeo’s orphan-drug exclusivity, stronger-than-guided launch traction, and updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Recent Street research around Precigen has focused on the implications of Papzimeo’s launch performance and the orphan-drug exclusivity decision, with several price targets adjusted to reflect these updates.
Analysis Article • Jun 21

Precigen (PGEN) Stock Could Be 79% Undervalued After FDA Exclusivity Win

Precigen (PGEN) is back in focus after the FDA granted orphan drug exclusivity to PAPZIMEOS for adult recurrent respiratory papillomatosis, limiting similar competing therapies for seven years and defining a clearer commercial runway. See our latest analysis for Precigen. The FDA decision comes after a period of strong momentum for Precigen, with the share price delivering a 46.95% 3 month share price return and a very large 1 year total shareholder return. However, the 5 year total...
Seeking Alpha • Feb 28

Precigen: UltraCAR-T Development Brings Another Side Of Pipeline Advancement

Summary BLA of PRGN-2012 for patients with Recurrent Respiratory Papillomatosis was accepted by FDA with a Priority Review date of August 27th of 2025. Marketing approval of PRGN-2012 for RRP would be huge because there is no FDA approved drugs for RRP. Also, there are an estimated 27,000 people in the United States who have it. PGEN is looking to form a strategic partnership or collaboration agreement to advance its UltraCAR-Ts. This technology is crucial because it could change CAR-T landscape for the better. PRGN-3006 is an UltraCAR-T being developed to target patients with Acute Myeloid Leukemia; PRGN-3008 is an UltraCAR-T targeting patients with CD19 solid tumors and autoimmune disorders. Read the full article on Seeking Alpha
Seeking Alpha • Feb 10

Precigen: Successful Proof Of Platform, But Cash Worries Remain

Summary Precigen's lead asset, PRGN-2012, shows promising results in treating Recurrent Respiratory Papillomatosis, achieving a 51% complete response rate and reducing surgical interventions. Financially, Precigen has a market cap of $468mn and a cash runway into 2026, but needs more funds for commercialization. The company is prioritizing PRGN-2012's development, restructuring operations, and cutting 20% of its workforce to extend its cash runway. Despite financial risks, Precigen's proven platforms and promising data make it a potential worthwhile investment, pending resolution of cash issues. Read the full article on Seeking Alpha
Analysis Article • Feb 28

We're Keeping An Eye On Precigen's (NASDAQ:PGEN) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jan 20

Precigen: RRP Targeting With AdenoVerse Technology Platform

Summary FDA agreed to allow phase 1/2 study to serve as the basis for being able to file for Accelerated Approval of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis. A BLA filing of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis is expected in the 2nd half of 2024. It is projected that it could earn $2 billion in peak sales globally of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis. PRGN-2009 which also uses the AdenoVerse technology has one phase 2 study targeting OPSCC underway and another one targeting recurrent/metastatic cervical cancer patients expected to begin in 2024. Read the full article on Seeking Alpha
Analysis Article • Nov 04

Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Jul 18

Is Precigen (NASDAQ:PGEN) Using Debt In A Risky Way?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

Earnings and Revenue Growth Forecasts

NasdaqGS:PGEN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028438278N/AN/A1
12/31/20272297581773
12/31/2026124-9-12-183
3/31/202632-383-117-115N/A
12/31/202510-430-90-88N/A
9/30/20256-426-76-73N/A
6/30/20254-124-70-66N/A
3/31/20254-157-75-70N/A
12/31/20244-126-77-68N/A
9/30/20244-140-84-76N/A
6/30/20244-135-78-70N/A
3/31/20245-97-68-63N/A
12/31/20236-96-68-67N/A
9/30/20237-85-67-67N/A
6/30/202322-73-75-73N/A
3/31/202323-79-68-65N/A
12/31/202227-80-70-65N/A
9/30/202229-84-72-64N/A
6/30/202215-103-66-57N/A
3/31/202216-108-66-58N/A
12/31/202114-111-63-56N/A
9/30/202130-124-64-58N/A
6/30/202150-125-64-60N/A
3/31/202177-110-71-66N/A
12/31/202032-104-85-77N/A
9/30/2020101-100-103-93N/A
6/30/202096-122-118-101N/A
3/31/202098-138-150-120N/A
12/31/201991-169N/A-136N/A
9/30/2019108-373N/A-141N/A
6/30/2019122-381N/A-143N/A
3/31/2019134-414N/A-138N/A
12/31/2018151-375N/A-124N/A
9/30/2018194-196N/A-121N/A
6/30/2018208-179N/A-114N/A
3/31/2018217-132N/A-109N/A
12/31/2017219-71N/A-104N/A
9/30/2017200-134N/A-94N/A
6/30/2017203-123N/A-88N/A
3/31/2017201-154N/A-77N/A
12/31/2016191-187N/A-49N/A
9/30/2016186-175N/A-19N/A
6/30/2016191-184N/A49N/A
3/31/2016183-176N/A45N/A
12/31/2015174-84N/A36N/A
9/30/2015163-33N/A14N/A
6/30/2015131-47N/A-45N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PGEN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.5%).

Earnings vs Market: PGEN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PGEN is expected to become profitable in the next 3 years.

Revenue vs Market: PGEN's revenue (42.4% per year) is forecast to grow faster than the US market (12.6% per year).

High Growth Revenue: PGEN's revenue (42.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PGEN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/28 11:08
End of Day Share Price 2026/06/26 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Precigen, Inc. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ying HuangBarclays
Derik de BruinBofA Global Research
Justin WalshB. Riley Securities, Inc.